TRIB - Trinity Biotech slides 7% on Q1 results

Trinity Biotech ([[TRIB]] -6.2%) reports Q1 revenue of $25.6M (+20.9% Y/Y), beating expectations by $1.6M.Clinical laboratory revenues increased to $23.7M, which represents an increase of 32.9% compared to Q1, 2020; the rise in revenue was primarily due to strong sales of products within our COVID-19 related portfolio of products, PCR Viral Transport Media products continuing to be the most significant contributor to revenue within that portfolio.Point-of-Care revenues decreased from $3.3M to $1.9M when compared to Q1, 2020, a decrease of 43.4%, primarily due to a delay in the issue of HIV rapid test orders from Africa as a result of COVID-19.Gross profit of $10.9M, representing a gross margin of 42.6% vs. 43.8% in Q1 2020.Research and Development expenses remained broadly flat at $1.4M.The profit after tax, before non-cash financial expenses for the quarter was $1.8M, vs. a profit of $0.4M last year.EPS diluted per ADR of $0.10 vs. $0.053 in Q1, 2020. ??Cash generated from operations during the quarter was $5.9M.Cash and cash equivalents

For further details see:

Trinity Biotech slides 7% on Q1 results